Organoid-based Anticancer Drug Susceptibility Testing

  • Model name

    ONCO SAIGE

  • Company name

    PODO Therapeutics Co., Ltd.

  • Certification

    IVDD/IVDR

  • Exporting Country

category

  • - CLINICAL & LABORATORY(IVD)

    • Other

Product detail

Onco Saige is an innovative platform capable of testing first-, second-, and third-generation anticancer therapies, including immunotherapy drugs, while incorporating patient-derived organoid (PDO) technology. It was developed to enhance the quality of life for cancer patients by providing standardized guidelines for the selection of optimal anticancer agents through accurate and personalized drug sensitivity testing.